We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic on Track with Covidien Synergy, Buys HeartWare
Read MoreHide Full Article
On Aug 26, 2016, we issued an updated research report on Medtronic plc (MDT - Free Report) . The company’s first-quarter fiscal 2017 earnings per share edged past the Zacks Consensus Estimate while revenues came close to our expectation.
The consolidated company demonstrated strong segmental performances on a constant currency, constant weeks (CCCW) basis, displaying successful integration and achievement of synergy targets. All four major business groups contributed to solid top-line growth which, according to the company, highlighted sustainability across groups and regions.
The consolidated company has successfully demonstrated strong segmental performances, reflecting successful integration and achievement of synergy targets. All four major business groups contributed to solid top-line growth on above-market revenue growth which, according to the company, highlighted sustainability across groups and regions.
The Covidien integration has been delivering robust operating leverage to date. The consolidation has started to work on strengthening the combined company’s long-term market competitiveness while driving sustainability and consistency in its long-term financial performance.
The combined entity is likely to generate about $27 billion in total annual revenue, including $3.7 billion from the emerging markets. Fiscal 2017 onwards, the deal is anticipated to prove considerably accretive to cash earnings. The transaction is also estimated to be neutral to the company’s earnings by fiscal 2019 and accretive thereafter.
We are also looking forward to Medtronic’s recently completed acquisition of HeartWare International, a global medical device manufacturer dedicated to serve patients with advanced heart failure, for a deal value of $1.1 billion. Medtronic believes the acquisition to expand its leadership across the heart failure continuum. This deal is also expected to aid Medtronic in offering much more advanced less-invasive heart pumps.
Medtronic is resorting to all possible means to boost growth. This includes penetration in emerging markets, expansion of its portfolio and restructuring of initiatives. These should benefit the company over the long term.
However, on the flip side, we note that the company is currently entangled in multiple legal issues which are weighing on the bottom line. Additionally, continued currency headwind, softer economy and tough competition headwinds keep us on the sidelines. Although during the first quarter, the currency impact was not significant, we can hardly rule out the possibility of severe currency impact on the company’s performance in future. For fiscal 2017, Medtronic estimates currency headwind to the tune of approximately 20 cents to 25 cents based on current exchange rates on earnings.
At present, Medtronic retains a Zacks Rank #3 (Hold).
Key Picks in the Sector
Some better-ranked medical product stocks are NuVasive, Inc. , Quidel Corp. (QDEL - Free Report) and GW Pharmaceuticals plc . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic on Track with Covidien Synergy, Buys HeartWare
On Aug 26, 2016, we issued an updated research report on Medtronic plc (MDT - Free Report) . The company’s first-quarter fiscal 2017 earnings per share edged past the Zacks Consensus Estimate while revenues came close to our expectation.
The consolidated company demonstrated strong segmental performances on a constant currency, constant weeks (CCCW) basis, displaying successful integration and achievement of synergy targets. All four major business groups contributed to solid top-line growth which, according to the company, highlighted sustainability across groups and regions.
The consolidated company has successfully demonstrated strong segmental performances, reflecting successful integration and achievement of synergy targets. All four major business groups contributed to solid top-line growth on above-market revenue growth which, according to the company, highlighted sustainability across groups and regions.
The Covidien integration has been delivering robust operating leverage to date. The consolidation has started to work on strengthening the combined company’s long-term market competitiveness while driving sustainability and consistency in its long-term financial performance.
The combined entity is likely to generate about $27 billion in total annual revenue, including $3.7 billion from the emerging markets. Fiscal 2017 onwards, the deal is anticipated to prove considerably accretive to cash earnings. The transaction is also estimated to be neutral to the company’s earnings by fiscal 2019 and accretive thereafter.
We are also looking forward to Medtronic’s recently completed acquisition of HeartWare International, a global medical device manufacturer dedicated to serve patients with advanced heart failure, for a deal value of $1.1 billion. Medtronic believes the acquisition to expand its leadership across the heart failure continuum. This deal is also expected to aid Medtronic in offering much more advanced less-invasive heart pumps.
Medtronic is resorting to all possible means to boost growth. This includes penetration in emerging markets, expansion of its portfolio and restructuring of initiatives. These should benefit the company over the long term.
However, on the flip side, we note that the company is currently entangled in multiple legal issues which are weighing on the bottom line. Additionally, continued currency headwind, softer economy and tough competition headwinds keep us on the sidelines. Although during the first quarter, the currency impact was not significant, we can hardly rule out the possibility of severe currency impact on the company’s performance in future. For fiscal 2017, Medtronic estimates currency headwind to the tune of approximately 20 cents to 25 cents based on current exchange rates on earnings.
At present, Medtronic retains a Zacks Rank #3 (Hold).
Key Picks in the Sector
Some better-ranked medical product stocks are NuVasive, Inc. , Quidel Corp. (QDEL - Free Report) and GW Pharmaceuticals plc . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>